ClinConnect ClinConnect Logo
Search / Trial NCT07022990

Improving Medication Management in World Trade Center Responders

Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jun 8, 2025

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Deprescribe Medication Management

ClinConnect Summary

This clinical trial is focused on helping World Trade Center (WTC) responders manage their medications better as they age. Many responders, especially those aged 50 and older, are taking multiple medications, which can lead to complications. The study aims to educate these individuals about their medications and encourage conversations with their doctors to safely reduce the number of unnecessary drugs they may be taking.

To participate in the trial, you need to be a WTC responder who is already part of a related study, be at least 50 years old, and currently taking specific types of medications, such as certain heartburn medications, sleep aids, or muscle relaxants. There are no exclusions, so if you meet these criteria, you might be eligible to join. Participants can expect to receive support and guidance on how to manage their medications more effectively, which could lead to better health outcomes and an improved quality of life.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • A WTC responder already enrolled in the "Promoting Healthy Aging Among WTC Responders: Frailty Trajectories and Intervention Strategies" study cohort
  • aged 50 years or older, and
  • * taking one of the five medication classes:
  • proton pump inhibitors (PPIs),
  • benzodiazepine (BZs) and
  • non-benzodiazepine sedative hypnotics ("Z-drugs"),
  • first-generation antihistamines (FGA), and
  • skeletal muscle relaxants (SMR).
  • Exclusion Criteria:
  • None

About Icahn School Of Medicine At Mount Sinai

The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Fred Ko, MD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported